Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Surgery.

University of Rochester Medical Center, Rochester, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Rochester, New York
Treatments:Chemotherapy, SurgeryHospital:University of Rochester Medical Center
Drugs:Journal:Link
Date:Oct 2002

Description:

Patients & Treatment: This Phase III study involved a total of 73 patients with stage IIIA non-small-cell lung cancer. Patients were divided into 5 groups. Group 1 (7 patients) received three drugs (cisplatin (platinol), vinblastine (velban), and mitomycin-C) in conjunction with surgery. Group 2 (9 patients) received the same drugs in conjunction with radiotherapy. Group 3 (12 patients) received only the drugs cisplatin and vinblastine. Group 4 (22 patients) received two drugs (cisplatin and vinblastine) with surgery. Group 5 (23 patients) received two drugs (cisplatin and vinblastine) with radiotherapy.

Toxicity: For the surgery plus chemotherapy groups (Groups 1 and 4) there were two toxic deaths (one late pulmonary toxicity and one pulmonary embolus). There were also hematologic toxicities.

Results: For the surgery plus chemotherapy groups (Groups 1 and 4), median survival was 19.4 months.

Correspondence: David W. Johnstone, MD




Back